The association between symptoms and microbiologically defined response to tuberculosis treatment

Annals of the American Thoracic Society

Volumn 10, Issue 1, 2013, Pages 18-25

  Hales, Craig M ^a   Heilig, Charles M ^a   Chaisson, Richard ^b   Leung, Chi Chiu ^c   Chang, Kwok Chiu ^c   Goldberg, Stefan V ^a   Gordin, Fred ^d   Johnson, John L ^e,f   Muzanyi, Grace ^g   Saukkonen, Jussi ^h   Vernon, Andrew ^a   Villarino, M Elsa ^a   Burman, William J ⁱ  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Hong Kong Department of Health   (Hong Kong)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cough; Drug treatment; Recurrence; Treatment failure; Tuberculosis

Indexed keywords

ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE;

ADULT; ARTICLE; BACTERIAL LOAD; BACTERIUM CULTURE; COUGHING; DISEASE SEVERITY; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; SWEAT; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 84878059660     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201207-038OC     Document Type: Article

References (21)

1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-S279.
2. Food and Drug Administration. Issues in the design of clinical trials of antimycobacterial drugs for treatment of tuberculosis; public workshop [Internet]. 2009. [updated September 23, 2009; accessed January 25, 2011]. Available from: http://www.fda.gov/Drugs/NewsEvents/ucm168975.htm.
3. Wunderink RG. Surrogate markers and microbiologic end points. Clin Infect Dis 2010;51(Suppl 1):S126-S130.
4. Johann-Liang R, Zalkikar J, Powers JH. Correlation between bacteriologic and clinical endpoints in trials of acute otitis media. Pediatr Infect Dis J 2003;22:936-937, author reply 937.
5. Dhuria M, Sharma N, Narender Pal S, Ram Chander J, Saha R, Gopal Krishan I. A study of the impact of tuberculosis on the quality of life and the effect after treatment with dots. Asia Pac J Public Health 2009;21: 312-320.
6. Marra CA, Marra F, Colley L, Moadebi S, Elwood RK, Fitzgerald JM. Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection. Chest 2008;133:396-403.
7. Guo N, Marra F, Marra CA. Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes 2009; 7:14.
8. Chang B, Wu AW, Hansel NN, Diette GB. Quality of life in tuberculosis: a review of the English language literature. Qual Life Res 2004;13: 1633-1642.
9. Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS ONE 2009;4: e5080.
10. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, Weis SE. Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest 2007;132:1591-1598.
11. Tuberculosis Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons. Lancet 2002;360:528-534.
12. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Relapse with rifamycin monoresistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid. Lancet 1999; 353:1843-1847.
13. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
14. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-280.
15. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006;173:350-356.
16. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ. Recurrent tuberculosis in the united states and canada: Relapse or reinfection? Am J Respir Crit Care Med 2004;170:1360-1366.
17. Diggle P, Liang K-Y, Zeger SL. Analysis of longitudinal data. New York: Clarendon Press; 1994.
18. R Development Core Team. R: A language and environment for statistical computing. 2.10.1 ed. Vienna, Austria: R Foundation for Statistical Computing; 2009.
19. Mitchison D. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147: 1062-1063.
20. Bark CM, Dietze R, Okwera A, Quelapio MI, Thiel BA, Johnson JL. Clinical symptoms and microbiological outcomes in tuberculosis treatment trials. Tuberculosis (Edinb) 2011;91:601-604.
21. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15:S282-S295.